Bioinformatics analysis-based screening of circRNA gene with mainstream expression trend in colorectal cancer and construction of a coexpression regulatory network

Nutritional ketosis modulates the methylation of cancer-related genes in patients with obesity and in breast cancer cells

Scientific evidence demonstrates that a very low-calorie ketogenic diet (VLCKD) is effective and beneficial in the treatment of obesity, capable of reversing the methylome associated with obesity and has immunomodulatory capacity. This effect is in part promoted by nutritional ketosis and could be involved in counteracting obesity-related cancer. The aim of this study was to evaluate the effect of nutritional ketosis on the methylation of genes related to tumor processes in patients with obesity and in breast cancer cells. Based on methylome data (Infinium MethylationEPIC BeadChip, Illumina) from patients with obesity treated with a VLCKD for weight loss (n = 10; n = 5 women, age = 48.8 ± 9.20 years, BMI = 32.9 ± 1.4 kg/m2), genes belonging to cancer-related pathways were specifically evaluated and further validated in vitro in MDA-MB-231 (triple negative) and MCF7 (RE positive) breast tumor cells pretreated for 72 h with βOHB, the main ketone body, secretome from visceral (VATs) or subcutaneous (SATs) adipose tissue of patients with obesity. The cell tumoral phenotype was evaluated by proliferation assay and expression of cancer-related genes. VLCKD-induced nutritional ketosis promoted changes in the methylation of 18 genes (20 CpGs; 17 hypomethylated, 3 hypermethylated) belonged to cancer-related pathways with MAPK10, CCN1, CTNNA2, LAMC3 and GLI2 being the most representative genes. A similar pattern was observed in the MDA-MB-231 cells treated with β-OHB, without changes in MCF7. These epigenetic changes paralleled the tumoral phenotype modulated by the treatments. Taking together these results highlight the potential role of VLCKD as an adjuvant to anticancer treatment in groups more susceptible to the development of cancer such as patients with obesity, exerting epigenetic regulation through nutritional ketosis and weight loss.

hsa_circ_0000520 Serves as a Prognostic Biomarker for Colorectal Cancer and Promotes in the Disease Progression

Background/Aims

Colorectal cancer (CRC) constitutes one of the prevalent malignancies within the gastrointestinal tract and serves as a primary contributor to cancer-related mortalities. This investigation sought to investigate the expression and prognostic significance of hsa_circ_0000520 in CRC and to evaluate its impact on the onset of CRC.

Materials and Methods

The levels of hsa_circ_0000520 were measured via quantitative real-time polymerase chain reaction (qRTPCR). To delve into the mechanism through which circ_0000520 impacts CRC and to assess the cellular behavior of CRC cells, a series of experiments including the CCK-8, transwell assay, flow cytometer assay, cell cloning formation, dual-luciferase reporter assay, and bioinformatics method were performed.

Results

The expression levels of hsa_circ_0000520 were markedly elevated in CRC cells and tissue specimens, and this elevation was correlated with a low survival rate. hsa_circ_0000520 affected CRC cell function via the miR-542-3p/MYH9 axis, thus exacerbating cancer progression.

Conclusion

hsa_circ_0000520 functions as a predictive biomarker for the prognosis of CRC and participates in its progression. hsa_ circ_0000520 emerges as a new treatment strategy for CRC patients.

Correction: Bioinformatics analysis-based screening of circRNA gene with mainstream expression trend in colorectal cancer and construction of a coexpression regulatory network

[This corrects the article DOI: 10.1371/journal.pone.0295126.].